Goldman Sachs Group Inc. raised its position in shares of CytRx Corporation (NASDAQ:CYTR) by 795.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 703,465 shares of the biotechnology company’s stock after purchasing an additional 624,863 shares during the quarter. Goldman Sachs Group Inc. owned 0.42% of CytRx Corporation worth $441,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently bought and sold shares of CYTR. Vanguard Group Inc. increased its holdings in shares of CytRx Corporation by 53.9% during the second quarter. Vanguard Group Inc. now owns 4,823,123 shares of the biotechnology company’s stock worth $3,024,000 after buying an additional 1,689,874 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of CytRx Corporation in the first quarter valued at approximately $264,000. LMR Partners LLP bought a new position in CytRx Corporation in the second quarter valued at approximately $235,000. Finally, SG Americas Securities LLC bought a new position in CytRx Corporation in the first quarter valued at approximately $102,000. 41.78% of the stock is currently owned by institutional investors and hedge funds.
Separately, ValuEngine upgraded shares of CytRx Corporation from a “sell” rating to a “hold” rating in a research note on Friday, July 28th.
Shares of CytRx Corporation (NASDAQ:CYTR) opened at $2.14 on Friday. CytRx Corporation has a twelve month low of $1.71 and a twelve month high of $6.00.
CytRx Corporation Profile
CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy.